• Explore /
  • Poster
  • / An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).

An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).

Abstract Poster

Authors

null

Jia Fan

Department of Liver Surgery & Transplantation Center, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China;

Jia Fan , Shukui Qin , Hui-Chuan Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

CTR20222433

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS628)

DOI

10.1200/JCO.2023.41.4_suppl.TPS628

Abstract #

TPS628

Poster Bd #

N17

Abstract Disclosures

Similar Posters

First Author: Ghassan K. Abou-Alfa

First Author: Ciro Celsa

First Author: Oxana V. Crysler

First Author: Claudia A.M. Fulgenzi